Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.40 |
| ▸ | DRD3 | P35462 | 8/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 6/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7003217 | 0.89 | DRD2 (0.41) | DRD2DRD3HDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL7001226 | 0.88 | HDAC3 (0.41) | DRD2DRD3HDAC3HDAC4HDAC1 | |
| SCHEMBL7002574 | 0.87 | CTSL (0.44) | DRD2DRD3HDAC3HDAC4HDAC1 | |
| SCHEMBL7004878 | 0.84 | USP30 (0.42) | DRD2DRD3HDAC3HDAC4HDAC1 | |
| SCHEMBL7006730 | 0.84 | KDM4E (0.44) | DRD2DRD3HTR1ANAMPT | |
| SCHEMBL7008105 | 0.82 | MTNR1A (0.50) | DRD2DRD3HTR1A | |
| SCHEMBL7006541 | 0.81 | DRD2 (0.42) | DRD2DRD3HTR1APARP1 | |
| SCHEMBL7005337 | 0.80 | HTR1A (0.38) | DRD2DRD3HTR1APARP1 | |
| SCHEMBL7003016 | 0.80 | THRB (0.42) | HTR1ANAMPT | |
| SCHEMBL7009570 | 0.78 | ROCK2 (0.42) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105118-A1 | Tricyclic quinazolinediones | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-06-05 | — | — | US | disclosed |
| EP-1288216-A1 | TRICYCLIC QUINAZOLINEDIONES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105118-A1 | Tricyclic quinazolinediones | PARP1, PARP11, PARP2 | DRD2 1008/4885DRD3 878/4885HDAC3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.